Skip to main
CRBP
CRBP logo

CRBP Stock Forecast & Price Target

CRBP Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Corbus Pharmaceuticals Holdings Inc. presents a positive outlook for its stock primarily due to its promising development pipeline, particularly with CRB-701. Key opinion leaders (KOLs) highlight CRB-701's potential to significantly improve patient survival rates in later lines of treatment thanks to its favorable safety profile and dosing frequency, setting it apart from competitors in the antibody-drug conjugate market. Additionally, robust trial enrollment and a well-structured “all comers” trial design suggest strong clinical and regulatory alignment, further enhancing the likelihood of meeting registrational deadlines and addressing high unmet medical needs.

Bears say

Corbus Pharmaceuticals Holdings Inc faces several fundamental challenges that contribute to a negative outlook for its stock. Despite favorable safety metrics for CRB-701 compared to competitors, the inherent risk of clinical and regulatory failures looms large, with potential delays in drug approvals and efficacy concerns for its pipeline candidates, including CRB-701 and CRB-913. Additionally, broader commercial challenges and the competitive landscape in oncology may undermining the company's ability to achieve sales estimates, posing further risks to its financial performance and market valuation.

CRBP has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corbus Pharmaceuticals Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corbus Pharmaceuticals Holdings (CRBP) Forecast

Analysts have given CRBP a Buy based on their latest research and market trends.

According to 5 analysts, CRBP has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corbus Pharmaceuticals Holdings (CRBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.